Endoscopy in the coagulopathic patient

Research output: Contribution to journalArticle

Abstract

PURPOSE OF REVIEW: The presence of coagulopathy in patients profoundly affects the performance of gastrointestinal endoscopy. However, the coagulopathy in chronic liver disease (CLD) and therapeutic anticoagulation to lower thromboembolic risk are different. In this review, we briefly discuss the hemostatic alterations in CLD leading to coagulopathy and the periprocedure management of antithrombotic medications in patients needing emergency or elective gastrointestinal endoscopy. RECENT FINDINGS: Prothrombin time (PT) and international normalized ratio (INR) are unreliable measures of bleeding risk and hemostasis in CLD. Therefore, expert opinion advises no preprocedure fresh frozen plasma (FFP) infusion to correct the INR. There has been a proliferation of and increasing use of antithrombotic medications for therapeutic anticoagulation. Their management depends on the gastrointestinal endoscopy procedure bleeding risk, the acuity of the procedure, and the underlying thromboembolic risk of the patient. SUMMARY: Cirrhotic coagulopathy features a rebalancing of procoagulant and anticoagulant factors. PT and INR do not accurately measure this rebalanced hemostasis. Thus, expert opinion does not recommend FFP infusion to correct the PT or INR before performing gastrointestinal endoscopy. Management of therapeutic anticoagulation in endoscopy depends on the acuity of the indication, the procedure bleeding risk, and the thromboembolic risk of stopping anticoagulation. At present, there are only expert opinion recommendations concerning periendoscopy coagulopathy management in CLD and in therapeutic anticoagulation. More controlled clinical studies will clarify bleeding risks when performing gastrointestinal procedures in these patients and better direct patient care. Until then, clinical management of antithrombotic medications are based an individual patient's medical conditions and available options for treatment.

Original languageEnglish (US)
Pages (from-to)401-407
Number of pages7
JournalCurrent opinion in gastroenterology
Volume35
Issue number5
DOIs
StatePublished - Sep 1 2019

Fingerprint

Endoscopy
Gastrointestinal Endoscopy
International Normalized Ratio
Liver Diseases
Prothrombin Time
Expert Testimony
Chronic Disease
Hemorrhage
Hemostasis
Therapeutics
Hemostatics
Anticoagulants
Patient Care
Emergencies

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Endoscopy in the coagulopathic patient. / Bull-Henry, Kathy.

In: Current opinion in gastroenterology, Vol. 35, No. 5, 01.09.2019, p. 401-407.

Research output: Contribution to journalArticle

@article{d0e8c1fe7465413ea15bdd671746f0e9,
title = "Endoscopy in the coagulopathic patient",
abstract = "PURPOSE OF REVIEW: The presence of coagulopathy in patients profoundly affects the performance of gastrointestinal endoscopy. However, the coagulopathy in chronic liver disease (CLD) and therapeutic anticoagulation to lower thromboembolic risk are different. In this review, we briefly discuss the hemostatic alterations in CLD leading to coagulopathy and the periprocedure management of antithrombotic medications in patients needing emergency or elective gastrointestinal endoscopy. RECENT FINDINGS: Prothrombin time (PT) and international normalized ratio (INR) are unreliable measures of bleeding risk and hemostasis in CLD. Therefore, expert opinion advises no preprocedure fresh frozen plasma (FFP) infusion to correct the INR. There has been a proliferation of and increasing use of antithrombotic medications for therapeutic anticoagulation. Their management depends on the gastrointestinal endoscopy procedure bleeding risk, the acuity of the procedure, and the underlying thromboembolic risk of the patient. SUMMARY: Cirrhotic coagulopathy features a rebalancing of procoagulant and anticoagulant factors. PT and INR do not accurately measure this rebalanced hemostasis. Thus, expert opinion does not recommend FFP infusion to correct the PT or INR before performing gastrointestinal endoscopy. Management of therapeutic anticoagulation in endoscopy depends on the acuity of the indication, the procedure bleeding risk, and the thromboembolic risk of stopping anticoagulation. At present, there are only expert opinion recommendations concerning periendoscopy coagulopathy management in CLD and in therapeutic anticoagulation. More controlled clinical studies will clarify bleeding risks when performing gastrointestinal procedures in these patients and better direct patient care. Until then, clinical management of antithrombotic medications are based an individual patient's medical conditions and available options for treatment.",
author = "Kathy Bull-Henry",
year = "2019",
month = "9",
day = "1",
doi = "10.1097/MOG.0000000000000559",
language = "English (US)",
volume = "35",
pages = "401--407",
journal = "Current Opinion in Gastroenterology",
issn = "0267-1379",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Endoscopy in the coagulopathic patient

AU - Bull-Henry, Kathy

PY - 2019/9/1

Y1 - 2019/9/1

N2 - PURPOSE OF REVIEW: The presence of coagulopathy in patients profoundly affects the performance of gastrointestinal endoscopy. However, the coagulopathy in chronic liver disease (CLD) and therapeutic anticoagulation to lower thromboembolic risk are different. In this review, we briefly discuss the hemostatic alterations in CLD leading to coagulopathy and the periprocedure management of antithrombotic medications in patients needing emergency or elective gastrointestinal endoscopy. RECENT FINDINGS: Prothrombin time (PT) and international normalized ratio (INR) are unreliable measures of bleeding risk and hemostasis in CLD. Therefore, expert opinion advises no preprocedure fresh frozen plasma (FFP) infusion to correct the INR. There has been a proliferation of and increasing use of antithrombotic medications for therapeutic anticoagulation. Their management depends on the gastrointestinal endoscopy procedure bleeding risk, the acuity of the procedure, and the underlying thromboembolic risk of the patient. SUMMARY: Cirrhotic coagulopathy features a rebalancing of procoagulant and anticoagulant factors. PT and INR do not accurately measure this rebalanced hemostasis. Thus, expert opinion does not recommend FFP infusion to correct the PT or INR before performing gastrointestinal endoscopy. Management of therapeutic anticoagulation in endoscopy depends on the acuity of the indication, the procedure bleeding risk, and the thromboembolic risk of stopping anticoagulation. At present, there are only expert opinion recommendations concerning periendoscopy coagulopathy management in CLD and in therapeutic anticoagulation. More controlled clinical studies will clarify bleeding risks when performing gastrointestinal procedures in these patients and better direct patient care. Until then, clinical management of antithrombotic medications are based an individual patient's medical conditions and available options for treatment.

AB - PURPOSE OF REVIEW: The presence of coagulopathy in patients profoundly affects the performance of gastrointestinal endoscopy. However, the coagulopathy in chronic liver disease (CLD) and therapeutic anticoagulation to lower thromboembolic risk are different. In this review, we briefly discuss the hemostatic alterations in CLD leading to coagulopathy and the periprocedure management of antithrombotic medications in patients needing emergency or elective gastrointestinal endoscopy. RECENT FINDINGS: Prothrombin time (PT) and international normalized ratio (INR) are unreliable measures of bleeding risk and hemostasis in CLD. Therefore, expert opinion advises no preprocedure fresh frozen plasma (FFP) infusion to correct the INR. There has been a proliferation of and increasing use of antithrombotic medications for therapeutic anticoagulation. Their management depends on the gastrointestinal endoscopy procedure bleeding risk, the acuity of the procedure, and the underlying thromboembolic risk of the patient. SUMMARY: Cirrhotic coagulopathy features a rebalancing of procoagulant and anticoagulant factors. PT and INR do not accurately measure this rebalanced hemostasis. Thus, expert opinion does not recommend FFP infusion to correct the PT or INR before performing gastrointestinal endoscopy. Management of therapeutic anticoagulation in endoscopy depends on the acuity of the indication, the procedure bleeding risk, and the thromboembolic risk of stopping anticoagulation. At present, there are only expert opinion recommendations concerning periendoscopy coagulopathy management in CLD and in therapeutic anticoagulation. More controlled clinical studies will clarify bleeding risks when performing gastrointestinal procedures in these patients and better direct patient care. Until then, clinical management of antithrombotic medications are based an individual patient's medical conditions and available options for treatment.

UR - http://www.scopus.com/inward/record.url?scp=85070851979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070851979&partnerID=8YFLogxK

U2 - 10.1097/MOG.0000000000000559

DO - 10.1097/MOG.0000000000000559

M3 - Article

C2 - 31343417

AN - SCOPUS:85070851979

VL - 35

SP - 401

EP - 407

JO - Current Opinion in Gastroenterology

JF - Current Opinion in Gastroenterology

SN - 0267-1379

IS - 5

ER -